Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Ligand Pharmaceuticals Incorporated price momentum is very positive. Ligand Pharmaceuticals Incorporated has good growth characteristics. Ligand Pharmaceuticals Incorporated is not very popular among insiders. Ligand Pharmaceuticals Incorporated is a mediocre stock to choose.
Log in to see more information.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquirin...
LGND Fundamental Data by TradingView

News

Principal Financial Group Inc. Sells 3,355 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Principal Financial Group Inc. Sells 3,355 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ticker Report Principal Financial Group Inc. lowered its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.6% in the second quarter, according to its most recent Form 13F filing with...\n more…

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Simply Wall St Ligand Pharmaceuticals' (NASDAQ:LGND) stock is up by a considerable 27% over the past three months. However, we wonder...\n more…

Rothschild Investment LLC Acquires Shares of 406 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Rothschild Investment LLC Acquires Shares of 406 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Zolmax Rothschild Investment LLC acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and...\n more…

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Neph
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Neph

Business Wire Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration...\n more…

Short Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expands By 10.3%
Short Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expands By 10.3%

Ticker Report Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) saw a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 1,060,000...\n more…

Louisiana State Employees Retirement System Acquires 400 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Louisiana State Employees Retirement System Acquires 400 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ticker Report Louisiana State Employees Retirement System grew its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.9% in the second quarter, according to the company in its most...\n more…